122 related articles for article (PubMed ID: 6198636)
1. [Results of the use of chlormadinone and farlutal depot in hormonal therapy of uterine cancer].
Witczak-Ploch E
Nowotwory; 1983; 33(2):129-38. PubMed ID: 6198636
[No Abstract] [Full Text] [Related]
2. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
Husslein P; Egarter C; Eppel W; Salzer H; Spona J
Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
[TBL] [Abstract][Full Text] [Related]
4. [Intrauterine pregnancy with uterine myoma after downregulation with GnRH analogs].
Naether O; Diedrich K
Geburtshilfe Frauenheilkd; 1992 Feb; 52(2):121-2. PubMed ID: 1314757
[TBL] [Abstract][Full Text] [Related]
5. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
[TBL] [Abstract][Full Text] [Related]
6. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
[TBL] [Abstract][Full Text] [Related]
7. [Effect of medroxyprogesterone acetate on cerebral blood flow].
Ikeda T; Kaneko M; Mori N
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Mar; 42(3):285-6. PubMed ID: 2139690
[No Abstract] [Full Text] [Related]
8. Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.
Etienne MC; Milano G; René N; Benedetti MS; Efthymiopoulos C; Vo Van ML; Hurteloup P; Montcuquet P; Frenay M; Namer M
J Pharm Sci; 1991 Dec; 80(12):1130-2. PubMed ID: 1839998
[TBL] [Abstract][Full Text] [Related]
9. [Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer].
Thurzó L
Zentralbl Gynakol; 1990; 112(17):1111-5. PubMed ID: 2148245
[TBL] [Abstract][Full Text] [Related]
10. [Progestins in combined treatment of endometrial cancer].
Voznyĭ EK; Titova VA
Sov Med; 1990; (9):102-7. PubMed ID: 2148437
[No Abstract] [Full Text] [Related]
11. High-dose depot-medroxyprogesterone acetate (DMPA) - effects on lipid and lipoprotein metabolism.
Crona N; Enk L; Samsioe G; Silfverstolpe G; Skryten A
Eur J Obstet Gynecol Reprod Biol; 1983 Oct; 16(2):97-105. PubMed ID: 6227506
[TBL] [Abstract][Full Text] [Related]
12. Changes in apolipoprotein AI after treatment with high-dose medroxyprogesterone acetate.
Crona N; Enk L; Friberg LG; Samsioe G; Silfverstolpe G
Gynecol Obstet Invest; 1984; 18(1):16-20. PubMed ID: 6235158
[TBL] [Abstract][Full Text] [Related]
13. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate.
Kline RC; Freedman RS; Jones LA; Atkinson EN
Cancer Treat Rep; 1987 Mar; 71(3):327-8. PubMed ID: 2949831
[No Abstract] [Full Text] [Related]
14. [A case of marked effectiveness using medroxyprogesterone acetate (MPA) in lung metastases of cancer of the uterine body].
Takeda M; Kubo K; Fukushima M; Hirayama J; Sekiguchi M
Gan To Kagaku Ryoho; 1990 Oct; 17(10):2113-7. PubMed ID: 2145808
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced endometrial adenocarcinoma with cyclic sequential ethinyl estradiol and medroxyprogesterone acetate.
Tatman JL; Freedman RS; Scott W; Atkinson EN
Eur J Cancer Clin Oncol; 1989 Nov; 25(11):1619-21. PubMed ID: 2531671
[TBL] [Abstract][Full Text] [Related]
16. Sequential Gn-RH superagonist and medroxyprogesterone acetate treatment of uterine leiomyomata.
Benagiano G; Morini A; Aleandri V; Piccinno F; Primiero FM; Abbondante G; Elkind-Hirsch K
Int J Gynaecol Obstet; 1990 Dec; 33(4):333-43. PubMed ID: 1979288
[TBL] [Abstract][Full Text] [Related]
17. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
Stockdale AD; Chapman D; Mould GP; Rostom AY
Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
[TBL] [Abstract][Full Text] [Related]
18. ACTH and cortisol plasma levels in cancer patients treated with medroxyprogesterone acetate at high dosages.
Papaleo C; Carella C; Zito GA; Figlia A; Capuano F; Amato G
Chemioterapia; 1984 Aug; 3(4):220-2. PubMed ID: 6099752
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of juvenile adenomatous hyperplasia of the endometrium by progesterone stimulation].
Krafft W
Zentralbl Gynakol; 1989; 111(12):846-8. PubMed ID: 2475003
[No Abstract] [Full Text] [Related]
20. High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy.
Mangioni C; Franceschi S; La Vecchia C; D'Incalci M
Gynecol Oncol; 1981 Dec; 12(3):314-8. PubMed ID: 6458544
[No Abstract] [Full Text] [Related]
[Next] [New Search]
